F. Montagnani, C. Migali and G. Fiorentini, “Progression-free Survival in Bevacizumab-based First-line Treatment for Pa-tients with Metastatic Colorectal Cancer: Is It a Really Good End Point?” Journal of Clinical Oncology, Vol. 27, No. 28, 2009, pp. e132-133.

has been cited by the following article:

• TITLE: Diminishing Returns in the Treatment of Metastatic Colorectal Cancer: Are Patients Reaching a Survival Plateau

  AUTHORS: Lencioni Riccardo, Chen James

  KEYWORDS: Colorectal Cancer, Chemotherapy, Molecular Targeted Agents

  JOURNAL NAME: Journal of Cancer Therapy, Vol.1 No.4, December 30, 2010

  ABSTRACT: Despite the evolution of treatment for metastatic colorectal cancer (MCRC) over the past decade, improvements in survival endpoints have appeared to reach a plateau. The addition of expensive targeted biologic agents to the therapeutic armamentarium against MCRC have not drastically increased survival, particularly in the realm of second and third line patients, as tumor resistance remains an issue. Original approaches to treating MCRC are needed in order to raise the apparent survival ceiling in these patients.